The following slide presentations have been made available by the presenters. Some files are large and may have long download times. These files are for your review only. They should not be distributed without written consent from the authors. The files are in Adobe7 Acrobat PDF format. Click herefor a free copy of the latest Adobe PDF Reader.
Cancer Progress 2011 Slides
March 8-9, 2011
The Westin New York at Times Squere
Diagnostics
Steven D. Averbuch MD, VP, Early Global Clinical Research Oncology & Head, Pharmacodiagnostics Bristol-Myers Squibb
Oncology Market Overview: Barriers, Challenges and Value
Bill Bagwell, RPh, Senior Vice President, Clinical and Scientific Assessment, Kantar Health & Rhoda Dunn, Account Director, Market Access, Kantar Health
Challenges for use of CTCs as a Diagnostic
Farideh Z. Bischoff, Ph.D., Interim CSO, Sr. Director, Translational Clinical Development Biocept, Inc.
Multi-Targeting to Potentiate Immunotherapy
Thomas Davis, MD, Senior Vice President and Chief Medical Officer, Celldex
BRAF inhibitors
Keith T. Flaherty, MD, Director, Developmental Therapeutics, Massachusetts General Hospital
New Targets Session 1 -An Update on PI3K, MEK, mTOR
Levi Garraway, MD, PhD, Associate Member, The Broad Institute (Melanoma)
Synthetic Lethality As A Strategy To Improve Molecularly Targeted Therapy
Erica Golemis, PhD, Professor, Deputy Chief Scientific Officer & Vice President, Co-Leader, Developmental Therapeutics, Co-Leader, Head and Neck Cancer Keystone, Director, High Throughput Screening and Translational Research Facility, Fox Chase Cancer Center
T-DM1 Breast Cancer
Ellie Guardino, MD, PhD, Medical Director, T-DM1, Genentech
Immunotherapy Targeting MUC1
Robert Kirkman, MD, President & CEO, Oncothyreon
Molecular Profiling, Prognostic and Predictive BioMarker and Genomic Strategies for Rational Combination of Targeted Therapies
Brian Leyland-Jones, MD, PhD, Emory University
Early Detection of Colorectal Cancer
Graham Lidgard, PhD, CSO, Exact Sciences
Endpoints to Evaluate Cancer Vaccines
H. Kim Lyerly, MD, Director, Duke Comprehensive Cancer Center , George Barth Geller Professor of Cancer Research, Duke University
New Targets Session 2
Ivor Royston , MD , Managing Member, Forward Ventures
Getting to proof-of-concept: novel strategies for phase II development
Christopher Slapak, MD, Distinguished Lilly Scholar – Oncology Business Unit – Exploratory/Pre-Clinical, Eli Lilly
Rapid Approval of New Medicines and Combos in Oncology
Jamey Skillings, MD, MSc, Vice President, Medical Affairs, Pfizer
Supporting Organization:
